Patents by Inventor Christoph Reinisch

Christoph Reinisch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO
    Publication number: 20230295245
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Application
    Filed: September 14, 2022
    Publication date: September 21, 2023
    Applicant: Valneva Austria GmbH
    Inventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
  • CpG-adjuvanted SARS-CoV-2 virus vaccine
    Patent number: 11684669
    Abstract: Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: June 27, 2023
    Assignees: Valneva Austria GmbH, Dynavax Technologies Corporation
    Inventors: Andreas Meinke, Michael Möhlen, Christoph Reinisch, Robert Schlegl, Christian Taucher, John Campbell, David Novack, Robert S. Janssen, Jürgen Heindl-Wruss
  • CORONAVIRUS VACCINES COMPRISING A TLR9 AGONIST
    Publication number: 20230092650
    Abstract: The present disclosure relates to immunogenic compositions comprising a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen, and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guano sine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against a SARS-CoV-2 in an individual in need thereof.
    Type: Application
    Filed: March 1, 2021
    Publication date: March 23, 2023
    Applicants: Dynavax Technologies Corporation, Valneva Austria GmbH
    Inventors: John D. Campbell, Robert S. Janssen, David Novack, Christian Taucher, Christoph Reinisch, Andreas Meinke, Michael Möhlen, Robert Schlegl, Jürgen Heindl-Wruss
  • CpG-ADJUVANTED SARS-CoV-2 VIRUS VACCINE
    Publication number: 20230038284
    Abstract: Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
    Type: Application
    Filed: September 10, 2021
    Publication date: February 9, 2023
    Applicants: Valneva Austria GmbH, Dynavax Technologies Corporation
    Inventors: Andreas Meinke, Michael Möhlen, Christoph Reinisch, Robert Schlegl, Christian Taucher, John Campbell, David Novack, Robert S. Janssen
  • Mutant fragments of OspA and methods and uses relating thereto
    Patent number: 11466058
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: October 11, 2022
    Assignee: Valneva Austria GmbH
    Inventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
  • CHIKUNGUNYA VACCINE FORMULATIONS
    Publication number: 20220288185
    Abstract: The present invention is related to novel liquid and lyophilized formulations of Chikungunya virus useful as vaccines and methods for their preparation.
    Type: Application
    Filed: August 10, 2020
    Publication date: September 15, 2022
    Applicant: Valneva SE
    Inventors: Christoph Reinisch, Robert Schlegl, Jürgen Heindl-Wruss
  • MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO
    Publication number: 20200239525
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Application
    Filed: December 4, 2019
    Publication date: July 30, 2020
    Applicant: Valneva Austria GmbH
    Inventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
  • Mutant fragments of OspA and methods and uses relating thereto
    Patent number: 10544194
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: January 28, 2020
    Assignee: Valneva Austria GmbH
    Inventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
  • MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO
    Publication number: 20170101446
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Application
    Filed: September 22, 2016
    Publication date: April 13, 2017
    Applicant: Valneva Austria GmbH
    Inventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
  • IC31 nanoparticles
    Patent number: 9248180
    Abstract: The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL5KLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 ?m.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: February 2, 2016
    Assignee: Valneva Austria GmbH
    Inventors: Benjamin Wizel, Karin Riedl, Karen Lingnau, Ursula Schlosser, Jürgen Wruss, Robert Schlegl, Michael Weber, Christoph Reinisch, Ljubomir Paucz, Christoph Klade, Jee Loon Look, Christian Ruiz, Robert Seid
  • MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETO
    Publication number: 20150232517
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Application
    Filed: July 8, 2013
    Publication date: August 20, 2015
    Inventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
  • IC31 NANOPARTICLES
    Publication number: 20150216967
    Abstract: The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL5KLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 ?m.
    Type: Application
    Filed: April 22, 2014
    Publication date: August 6, 2015
    Applicant: Valneva Austria GmbH
    Inventors: Benjamin Wizel, Karin Riedl, Karen Lingnau, Ursula Schlosser, Jürgen Wruss, Robert Schlegl, Michael Weber, Christoph Reinisch, Ljubomir Paucz, Christoph Klade, Jee Loon Look, Christian Ruiz, Robert Seid
  • 1C31 nanoparticles
    Patent number: 8765148
    Abstract: The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL5KLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 ?m.
    Type: Grant
    Filed: February 21, 2011
    Date of Patent: July 1, 2014
    Assignee: Valneva Austria GmbH
    Inventors: Benjamin Wizel, Karin Riedl, Karen Lingnau, Ursula Schlosser, Jürgen Wruss, Robert Schlegl, Michael Weber, Christoph Reinisch, Ljubomir Paucz, Christoph Klade, Jee Loon Look, Christian Ruiz, Robert Seid
  • IC31 NANOPARTICLES
    Publication number: 20120308618
    Abstract: The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL5KLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 ?m.
    Type: Application
    Filed: February 21, 2011
    Publication date: December 6, 2012
    Applicant: Intercell AG
    Inventors: Benjamin Wizel, Karin Riedl, Karen Lingnau, Ursula Schlosser, Jürgen Wruss, Robert Schlegl, Michael Weber, Christoph Reinisch, Ljubomir Paucz, Christoph Klade, Jee Loon Look, Christian Ruiz, Robert Seid
  • METHOD FOR PRODUCING PLASMID DNA ON A MANUFACTURING SCALE
    Publication number: 20100151530
    Abstract: A method for producing plasmid DNA on a manufacturing scale uses Escherichia coli K-12 strain JM108. The process results in high yield and homogeneity of plasmid DNA.
    Type: Application
    Filed: September 18, 2009
    Publication date: June 17, 2010
    Applicant: BOEHRINGER INGELHEIM RCV GMBH & CO. KG.
    Inventors: Hans HUBER, Claudia PACHER, Roman NECINA, Franz KOLLMANN, Christoph REINISCH
  • Method for producing plasmid DNA on a manufacturing scale
    Publication number: 20050233365
    Abstract: A method for producing plasmid DNA on a manufacturing scale uses Escherichia coli K-12 strain JM108. The process results in high yield and homogeneity of plasmid DNA.
    Type: Application
    Filed: April 8, 2005
    Publication date: October 20, 2005
    Applicant: Boehringer Ingelheim AUSTRIA GmbH
    Inventors: Hans Huber, Claudia Pacher, Roman Necina, Franz Kollmann, Christoph Reinisch